The Clinical and Forensic Toxicology of Z-drugs

  title={The Clinical and Forensic Toxicology of Z-drugs},
  author={Naren Gunja},
  journal={Journal of Medical Toxicology},
  • N. Gunja
  • Published 13 February 2013
  • Medicine
  • Journal of Medical Toxicology
The Z-drugs zolpidem, zopiclone, and zaleplon were hailed as the innovative hypnotics of the new millennium, an improvement to traditional benzodiazepines in the management of insomnia. Increasing reports of adverse events including bizarre behavior and falls in the elderly have prompted calls for caution and regulation. Z-drugs have significant hypnotic effects by reducing sleep latency and improving sleep quality, though duration of sleep may not be significantly increased. Z-drugs exert… 
Safety and Tolerability of Anxiolytics/Sedative-Hypnotics
Emerging evidence indicates that pregabalin, a pharmacological agent approved for the treatment of generalized anxiety disorder, also has the potential to lead to abuse and dependence, and is still valuable in the management of anxiety disorders and transient insomnia.
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
These drugs may improve sleep while successfully treating comorbid disorders, with a different side effect profile than the BZDs and Z-drugs.
In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving
  • N. Gunja
  • Psychology
    Journal of Medical Toxicology
  • 2013
The risk–benefit analysis of Z-drugs in the treatment of insomnia, particularly in the elderly, may not favor treatment due to the increased risks of falls and motor vehicle collisions.
Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use
The use of BZDs and z-hypnotics was strongly associated with the risk of dementia development, especially the short-acting BZD, z- Hypnotics, and concomitant use of multiple agents.
Sedative hypnotics overdose: Epidemiology, diagnosis and management
Zolpidem and Zolpidem Carboxylic Acid Results from Medication Monitoring.
Results from patient testing over a year's time are in agreement with the reported zolpidem results but the data observed herein for ZCA are not consistent with the earlier report, suggesting that monitoring ZCA may result in even higher levels of positivity.
Benzodiazepines and Other Sedatives, Hypnotics, and Anxiolytics
Benzodiazepines, barbiturates, and the nonbenzodiazepine “Z-drugs” have distinct, though variably overlapping, clinical manifestations of intoxication and withdrawal, which are described.
Clinical considerations of sleep related amnestic behaviours associated with zolpidem
An association between psychotic reactions and complex sleep related behavioural abnormalities in patients using zolpidem alone or in combination with other psychotropic medications is indicated.


Zolpidem for insomnia
approved doses of zolpidem are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia, however, favorable effects on sleep maintenance are observed less consistently.
Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon
Few clinically important interactions appear to have been reported in the literature with zaleplon, zolpidem and zopiclone, and the fact that these drugs are newer to the market and have not been as extensively studied as the conventional benzodiazepines may be the reason for this.
Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices.
As these drugs are also reported as drugs of abuse or in drug-facilitated crime, screening methods that simultaneously cover these drugs and also other drugs ofabuse were included in this review.
Zolpidem withdrawal delirium, seizure, and acute psychosis: Case reports and literature review
It is suggested that the normal criteria for the prescription of benzodiazepines also be used when prescribing non-benzodiazepine sedatives and hypnotics, as they act upon the same receptor, namely, the benzidiazepine-GABA-chloride complex.
Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics
The distinct clinical outcomes of zaleplon, zolpidem, zopicl one and eszopiclone may be explained by each drug’s unique GABAA receptor subunit selectivity and pharmacokinetic profile.
Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives
  • D. Drover
  • Biology
    Clinical pharmacokinetics
  • 2004
While zaleplon may be best indicated for the delayed onset of sleep, zolpidem and zopiclone may be better indicated for maintaining a complete night’s sleep.
Zopiclone: is it a pharmacologic agent for abuse?
  • N. Cimolai
  • Medicine, Psychology
    Canadian family physician Medecin de famille canadien
  • 2007
While many have suggested that the addictive potential for this and other "Z" drugs is less than for most benzodiazepines, caution should be taken when prescribing this agent for insomnia.
Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
Although zolpidem produced some psychomotor and memory impairment over the first few hours after administration, it had few next-day effects and was comparable or superior to flunitrazepam and flurazep am and comparable to other benzodiazepines in patients with insomnia.
Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
Zaleplon possesses a unique pharmacological profile, with an ultra-short half-life of about 1 hour, and selective binding to the BZ1(ω1) receptor subtypes of the GABAA receptor, that predicts a number of pharmacodynamic properties that account for a unique benefit-risk profile.
Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic
Flumazenil may be a safe and effective antidote in patients with Zolpidem overdosage and produce a clinically relevant hypnotic effect in five subjects and significantly impaired performance in all nine subjects up to 90 minutes after dosing.